The scope of clinical morbidity in sickle cell trait
Sickle cell trait (SCT), the heterozygous state of the sickle hemoglobin beta globin gene (HbAS) is carried by as many as 100 million individuals including up to 25% of the population in some regions of the World. Sickle cell trait is the best-characterized genetic polymorphism known to protect agai...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2014-10-01
|
| Series: | Egyptian Journal of Medical Human Genetics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1110863014000949 |
| _version_ | 1818847301271027712 |
|---|---|
| author | Azza A.G. Tantawy |
| author_facet | Azza A.G. Tantawy |
| author_sort | Azza A.G. Tantawy |
| collection | DOAJ |
| description | Sickle cell trait (SCT), the heterozygous state of the sickle hemoglobin beta globin gene (HbAS) is carried by as many as 100 million individuals including up to 25% of the population in some regions of the World. Sickle cell trait is the best-characterized genetic polymorphism known to protect against falciparum malaria. Although SCT was initially considered as a benign condition, data are accumulating of serious morbidities in SCT individuals including increased incidence of hematuria, renal papillary necrosis, renal failure and malignancy, thromboembolic disorders, splenic infarction as a high altitude complication, and exercise-related rhabdomyolysis and sudden death. Despite these associations, the average life span of individuals with sickle cell trait is similar to that of the general population. Nonetheless, given the large number of people with sickle cell trait, it is important that physicians be aware of these associations. The aim of this article is to review publications reporting and discussing morbidities in SCT individuals. |
| first_indexed | 2024-12-19T05:59:16Z |
| format | Article |
| id | doaj.art-c08558efae3d41fdbc7186a882313f2c |
| institution | Directory Open Access Journal |
| issn | 1110-8630 |
| language | English |
| last_indexed | 2024-12-19T05:59:16Z |
| publishDate | 2014-10-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Egyptian Journal of Medical Human Genetics |
| spelling | doaj.art-c08558efae3d41fdbc7186a882313f2c2022-12-21T20:33:22ZengSpringerOpenEgyptian Journal of Medical Human Genetics1110-86302014-10-0115431932610.1016/j.ejmhg.2014.08.008The scope of clinical morbidity in sickle cell traitAzza A.G. TantawySickle cell trait (SCT), the heterozygous state of the sickle hemoglobin beta globin gene (HbAS) is carried by as many as 100 million individuals including up to 25% of the population in some regions of the World. Sickle cell trait is the best-characterized genetic polymorphism known to protect against falciparum malaria. Although SCT was initially considered as a benign condition, data are accumulating of serious morbidities in SCT individuals including increased incidence of hematuria, renal papillary necrosis, renal failure and malignancy, thromboembolic disorders, splenic infarction as a high altitude complication, and exercise-related rhabdomyolysis and sudden death. Despite these associations, the average life span of individuals with sickle cell trait is similar to that of the general population. Nonetheless, given the large number of people with sickle cell trait, it is important that physicians be aware of these associations. The aim of this article is to review publications reporting and discussing morbidities in SCT individuals.http://www.sciencedirect.com/science/article/pii/S1110863014000949Sickle cell traitMorbidityRenalExerciseRhabdomyolysisThrombosis |
| spellingShingle | Azza A.G. Tantawy The scope of clinical morbidity in sickle cell trait Egyptian Journal of Medical Human Genetics Sickle cell trait Morbidity Renal Exercise Rhabdomyolysis Thrombosis |
| title | The scope of clinical morbidity in sickle cell trait |
| title_full | The scope of clinical morbidity in sickle cell trait |
| title_fullStr | The scope of clinical morbidity in sickle cell trait |
| title_full_unstemmed | The scope of clinical morbidity in sickle cell trait |
| title_short | The scope of clinical morbidity in sickle cell trait |
| title_sort | scope of clinical morbidity in sickle cell trait |
| topic | Sickle cell trait Morbidity Renal Exercise Rhabdomyolysis Thrombosis |
| url | http://www.sciencedirect.com/science/article/pii/S1110863014000949 |
| work_keys_str_mv | AT azzaagtantawy thescopeofclinicalmorbidityinsicklecelltrait AT azzaagtantawy scopeofclinicalmorbidityinsicklecelltrait |